Malcolm Ranson
Overview
Explore the profile of Malcolm Ranson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
3399
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Evans T, Dean E, Molife L, Lopez J, Ranson M, El-Khouly F, et al.
Br J Cancer
. 2019 Jan;
120(4):379-386.
PMID: 30679780
Background: This phase 1 study examined the safety, tolerability, pharmacokinetics and preliminary efficacy of eribulin-liposomal formulation (eribulin-LF) in patients with advanced solid tumours. Methods: Eligible patients with ECOG PS 0-1...
2.
Rodon J, Perez-Fidalgo A, Krop I, Burris H, Guerrero-Zotano A, Britten C, et al.
Cancer Chemother Pharmacol
. 2018 Jun;
82(2):285-298.
PMID: 29882016
Purpose: To determine the maximum tolerated dose (MTD) of BEZ235, an oral inhibitor of class I PI3K and mTOR complexes 1 and 2. Methods: We performed a phase I/Ib, multicenter,...
3.
Dearden S, Brown H, Jenkins S, Thress K, Cantarini M, Cole R, et al.
Lung Cancer
. 2017 Jun;
109:9-13.
PMID: 28577957
Objectives: Reliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib...
4.
Jamieson D, Griffin M, Sludden J, Drew Y, Cresti N, Swales K, et al.
Eur J Cancer
. 2016 Oct;
68:1-10.
PMID: 27693888
Purpose: We performed a multi-centre phase I study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the orally available small molecule mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor,...
5.
Planchard D, Brown K, Kim D, Kim S, Ohe Y, Felip E, et al.
Cancer Chemother Pharmacol
. 2016 Feb;
77(4):767-76.
PMID: 26902828
Purpose: Osimertinib (AZD9291) 80 mg once daily is approved by the US FDA for the treatment of patients with metastatic EGFR T790M-positive NSCLC whose disease has previously progressed on EGFR-TKI...
6.
Janne P, Yang J, Kim D, Planchard D, Ohe Y, Ramalingam S, et al.
N Engl J Med
. 2015 Apr;
372(18):1689-99.
PMID: 25923549
Background: The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an...
7.
Basu B, Dean E, Puglisi M, Greystoke A, Ong M, Burke W, et al.
Clin Cancer Res
. 2015 Mar;
21(15):3412-9.
PMID: 25805799
Purpose: AZD2014 is a novel, oral, m-TORC 1/2 inhibitor that has shown in vitro and in vivo efficacy across a range of preclinical human cancer models. Experimental Design: A rolling...
8.
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer
Calvert H, Twelves C, Ranson M, Plummer R, Fettner S, Pantze M, et al.
Anticancer Drugs
. 2014 Mar;
25(7):832-40.
PMID: 24637575
In vitro, erlotinib (0-30 µmol/l) and C-labelled midazolam (MDZ) (5 µmol/l) were incubated with human liver microsomes; separately, microsomes were preincubated with erlotinib (10 µmol/l) before the addition of MDZ....
9.
Aung K, Donald E, Ellison G, Bujac S, Fletcher L, Cantarini M, et al.
J Mol Diagn
. 2014 Mar;
16(3):343-9.
PMID: 24631158
BRAF mutation testing from circulating free DNA (cfDNA) using the amplification refractory mutation testing system (ARMS) holds potential as a surrogate for tumor mutation testing. Robust assay validation is needed...
10.
Li J, Liu Y, Qian J, Wu L, Kemp J, Nii M, et al.
Cancer Chemother Pharmacol
. 2012 May;
70(1):57-63.
PMID: 22618295
Purpose: The endothelin axis and the endothelin A (ET(A)) receptor have been implicated in tumor development and bone metastasis. This study aimed to investigate the pharmacokinetic (PK) and safety profiles...